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Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important cause of heart failure (HF). Current knowledge
on incidence, pathophysiology and natural history of HF in cardiomyopathies is limited, and distinct features of their therapeutic responses
have not been systematically addressed. Therefore, this position paper focuses on epidemiology, pathophysiology, natural history and latest
developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies. In DCM,
HF with reduced ejection fraction (HFrEF) has high incidence and prevalence and represents the most frequent cause of death, despite
improvements in treatment. In addition, advanced HF in DCM is one of the leading indications for heart transplantation. In HCM, HF with
preserved ejection (HFpEF) affects most patients with obstructive, and ∼10% of patients with non-obstructive HCM. A timely treatment is
important, since development of advanced HF, although rare in HCM, portends a poor prognosis. In RCM, HFpEF is common, while HFrEF
occurs later and more frequently in amyloidosis or iron overload/haemochromatosis. Irrespective of RCM aetiology, HF is a harbinger of
a poor outcome. Recent advances in our understanding of the mechanisms underlying the development of HF in cardiomyopathies have
significant implications for therapeutic decision-making. In addition, new aetiology-specific treatment options (e.g. enzyme replacement
therapy, transthyretin stabilizers, immunoadsorption, immunotherapy, etc.) have shown a potential to improve outcomes. Still, causative
therapies of many cardiomyopathies are lacking, highlighting the need for the development of effective strategies to prevent and treat HF in
cardiomyopathies.
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Introduction
Cardiomyopathies are a heterogeneous group of heart mus-
cle diseases, including dilated (DCM), hypertrophic (HCM),
restrictive (RCM), arrhythmogenic right ventricular (ARVC),
and non-classified cardiomyopathies that frequently present as the
syndrome of heart failure (HF).1 The variety of causes, multiple
underlying pathophysiological mechanisms and different pheno-
typic expressions influence their presentation and response to
treatment.1 Although patients with cardiomyopathies have been
represented in clinical trials, distinct features of their therapeutic
responses, relative to other aetiologies of HF, remain unknown.
For HF with reduced ejection fraction (< 40%, HFrEF), standard
therapy is indicated regardless of the underlying cause. In contrast,
for selected cardiomyopathies, specific treatment options have
been introduced, targeting specific underlying pathophysiology
(e.g. enzyme replacement therapy, transthyretin stabilizers, gene
silencing, monoclonal antibodies, immunotherapy, and others), thus
increasing the perspectives for improved outcomes. Therefore, this
position paper is focused on the incidence, pathophysiology, natural
history, outcomes and treatment of HF due to specific heart muscle
diseases, including DCM, HCM and RCM. Clinical presentation
of ARVC is usually dominated by ventricular arrhythmia, while
HF (right heart or biventricular) may occur in the minority of
patients with advanced disease. Considering its specific clinical






































.. Since HF is often the presenting clinical syndrome in DCM, HCM
and RCM, a practical stepwise approach has been suggested in
Figure 1. This approach should aid in clinical assessment of the
phenotype [including HFrEF; HF with mid-range ejection fraction
(40–49%); HF with preserved ejection fraction (≥ 50%, HFpEF)],
and aetiology of HF in cardiomyopathies.
Heart failure in dilated
cardiomyopathy
Incidence and prevalence of heart failure
in dilated cardiomyopathy
Dilated cardiomyopathy is characterized by ventricular dilatation
and systolic dysfunction in the absence of known abnormal loading
conditions or significant coronary artery disease.1 It is considered
one of the leading causes of HFrEF worldwide.2 The reported
prevalence of DCM in Europe and North America is ∼36 cases
per 100 000 population, and the annual incidence ranges between
5 and 7.9 cases per 100 000 population.3,4 The prevalence of DCM
is apparently lower in Eastern Asia (i.e. 14 cases per 100 000
in Japan),5 and it might be higher in Africa and Latin America
compared with Europe.6,7
Determining the incidence of HF in DCM is challenging, because
of variations in patient selection and underreporting of a specific
HF aetiology in many clinical trials and observational studies.
© 2019 The Authors
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Figure 1 Proposed clinical approach to the assessment of heart failure aetiology in cardiomyopathies. ACE, angiotensin-converting enzyme;
BNP, B-type natriuretic peptide; BP, blood pressure; CA, coronary angiography; CBC, complete blood count; CDI, colour Doppler imaging;
CK, creatine kinase, CMR, cardiac magnetic resonance; CRP, C-reactive protein; CT-CA, computed tomography coronary angiography; CWD,
continuous wave Doppler; DCM, dilated cardiomyopathy; ECG, electrocardiogram; ECV, extracellular volume; EMB, endomyocardial biopsy;
FDG, fluorodeoxyglucose; HCM, hypertrophic cardiomyopathy; HES, hypereosinophilic syndrome; HF, heart failure; HMDP, hydroxymethylene
diphosphonate; hsTnT, high sensitivity troponin T; IGF-1, insulin-like growth factor-1; LVEF, left ventricular ejection fraction; 99mTc-DPD,
technetium-99m 3,3-diphosphono-1,2-propanodicarboxylic acid; NT-proBNP, N-terminal pro B-type natriuretic peptide; PCR, polymerase
chain reaction; PET, positron emission tomography; PYP, pyrophosphate; PWD, pulsed wave Doppler; RCM, restrictive cardiomyopathy; SPECT,
single photon emission computed tomography; TDI, tissue Doppler imaging; TEE, transoesophageal echocardiography; TTE, transthoracic
echocardiography.
A recent study suggested that among patients with recent-onset
(< 6 months) DCM, 32% presented with HF and 66% had at
least one HF hospitalization before enrolment.8 Similarly, in a
contemporary cohort of 881 patients with DCM, HF was the most
common clinical presentation with a higher incidence in female
compared to male patients (i.e. 64% vs. 54%).9 Compared with
men, women presented with more advanced HF as indicated by
a higher proportion of the New York Heart Association (NYHA)
functional class III–IV symptoms (25% vs. 16%) and had a higher
frequency of left bundle branch block (LBBB) at diagnosis (43% vs.
23%).9 In another study, self-declared black race was associated
with a younger age and more severe HF symptoms at diagnosis
compared with white race.10 Furthermore, in a cohort of 3078
patients hospitalized for HF in Denmark and Sweden, individuals
with DCM were ∼10 years younger (median age, 64 years), and
had more severe symptoms and a lower left ventricular ejection
fraction (LVEF) (median LVEF, 24%) compared with other HF
patients.11
There is a broad variation in the reported prevalence of DCM






























. 12–35% of individuals.12–14 In observational studies of HF patients,
the prevalence of DCM ranged between 8% and 47%.11,15,16 In a
cohort of 156 013 patients hospitalized for HF in the USA, DCM
was the stated underlying cause in 31%.17 These estimates are
often approximate because the precise diagnosis of DCM may be
lacking in many patients who have not undergone a full diagnostic
evaluation.
Advanced HF in DCM accounts for > 40% of patients who
receive long-term mechanical circulatory support (MCS), either as
a bridge to heart transplantation or for destination therapy.18,19
DCM is the most common indication for heart transplantation both
in the adult and paediatric populations of advanced HF patients
and is the third most common indication for heart and lung
transplantation in adults.20–22 The proportion of patients being
transplanted for DCM compared with other HF aetiologies has
increased in recent years. Currently, in younger (18–39 years) and
middle-aged adults (40–59 years), 64% and 51%, respectively, of
all heart transplantations are attributable to DCM.22 After the
age of 60 years, DCM is the second most common indication for
heart transplantation preceded only by ischaemic heart disease,
© 2019 The Authors
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Figure 2 Aetiologies of dilated cardiomyopathy. HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HIV, human
immunodeficiency virus.
and accounts for 39% of all heart transplantations. Following
transplantation, patients with DCM generally have a favourable
short-term and long-term prognosis, with a median survival of
12.2 years.22
Pathophysiology of heart failure
in dilated cardiomyopathy
The pathophysiology of HF in DCM includes genetic causes,
as well as direct myocardial damage caused by infectious
or toxic agents, endocrine and metabolic abnormalities,
immune-mediated processes and peripartum cardiomyopathy
(PPCM)1 (Figure 2). The key morphological alterations under-
lying the pathophysiology of HF in DCM are summarized in
Figure 3.
A family history can be detected in 30–50% of cases23 and
a genetic determinant in up to 40% of DCM patients.1,24 How-
ever, this proportion is probably underestimated due to vari-
ability in disease penetrance and clinical presentation. To date,
more than 60 genes coding for sarcomere proteins, cytoskele-
ton, nuclear envelope, sarcolemma, ion channels and/or intercel-
lular junction molecules have been implicated in the pathogene-
sis of DCM.24,25 Amongst the most common is truncating titin
mutation, implicated in the pathogenesis of ∼13% and 25% of
non-familial and familial cases of DCM, respectively.26,27 Most muta-
tions have an autosomal dominant inheritance pattern, but there
are also X-linked, autosomal recessive and maternal transmission
(i.e. mitochondrial disorders) patterns. Routine genetic testing has
a relatively low yield (30–35%) and, as yet, few implications for












































.. and phospholamban gene mutations,28,29 which confer high risk
of arrhythmia and sudden cardiac death (SCD) that may lower
the threshold for an implantable cardioverter-defibrillator (ICD)
implantation.30 Duchenne muscular dystrophy is an X-linked disor-
der caused by the absence of a sarcolemmal protein, dystrophin,
in the skeletal muscle and the heart, which compromises the link
between the cytoskeleton and the extracellular matrix leading to
progressive muscle wasting, degeneration of cardiomyocytes and
replacement fibrosis.31 Myocardial fibrosis is associated with dete-
rioration in left ventricular (LV) systolic function and a propensity
for adverse outcomes.32 HF is one of the major causes of death
in patients with Duchenne muscular dystrophy; treatment with
perindopril and eplerenone has shown a capacity to slow cardiomy-
opathy progression.33,34
Viral infection followed by an (auto)immune activation in the
myocardium may play a major role in the development of HF in
DCM.35 Based on small animal studies, a three-phase model of
inflammatory heart muscle disease has been proposed. Initially,
direct cytotoxic effects can occur within a few days after viral
infection (e.g. enterovirus), leading to myocyte necrosis and acti-
vation of host innate (i.e. natural killer cells and macrophages)
and acquired (i.e. T lymphocytes) immunity. Later, (auto)immune
responses can occur in the subacute phase, lasting up to several
months. An increased activity of effector T lymphocytes has
been described, targeting both the virus and cellular components
(heat shock proteins, mitochondrial proteins, cardiac myosin,
etc.) by the mechanism of molecular mimicry.36 In addition
to inflammatory myocardial damage, autoantibodies directed
against the ADP/ATP carrier may contribute to LV dysfunction.37
Recently, myocardial inflammation characterized by the presence
© 2019 The Authors
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Figure 3 Characteristic alterations in cardiac morphology underlying heart failure in dilated cardiomyopathy.
of cytotoxic perforin-positive T lymphocytes has been shown
to predict subsequent deterioration of LV function over the
long-term follow-up period.38 These pathological processes may
cause substantial myocardial cell loss and trigger adverse ven-
tricular remodelling and replacement fibrosis, eventually leading
to the development of DCM and HF. At the same time, persis-
tent viral genomes have been detected in cardiac tissue without
DCM,39 emphasizing the important role of the host response.
Increased susceptibility to the development of DCM has been
linked to upregulation of genes for matrix metalloproteinase-9 and
type-1 procollagen in mast cells, which may result in pronounced
myocardial inflammation and necrosis, followed by replacement
fibrosis.40
Other infectious causes of DCM may have specific geographic
distributions. Most notable examples include human immunod-
eficiency virus (HIV) infection in sub-Saharan Africa, and Cha-
gas disease (Trypanosoma cruzi infection) in South America.41 The
pathogenesis of HIV-mediated DCM and HF is not completely
understood, whereas, myocardial damage in Chagas disease results
from diffuse fibrosis due to parasitic infestation, microcirculatory
damage and autoimmune mechanisms.42
Dilated cardiomyopathy may also occur in systemic
immune-mediated diseases (SIDs) that include autoimmune
and autoinflammatory disorders.43 In SIDs, autoantibodies may
promote inflammatory responses via immune complex formation
or may directly participate in cardiac damage, also mediated by
aberrant cellular immunity, resulting in myocyte loss, fibrosis and
the development of DCM. Genetic susceptibility could be of
crucial importance for the progression of HF after autoimmune
myocarditis, since evidence suggests that organ-specific autoanti-
bodies predict the development of DCM in asymptomatic relatives
















































.. The pathogenesis of PPCM is still not elucidated but several
contributing factors have been implicated.46,47 Excessive oxidative
stress in the last trimester of pregnancy, possibly caused by insuf-
ficient defence mechanisms, can promote activation of cathepsin
D and formation of a prolactin fragment with direct cardiotoxic
properties.48 Myocardial inflammation, viral infection, angiogenic
imbalance during pregnancy and autoimmune responses character-
ized by high titres of autoantibodies against the myocardial proteins
have been also implicated.49–52 Susceptibility to PPCM is appar-
ently higher in carriers of DCM-causing sarcomere gene muta-
tions, which supports a notion of a genetic predisposition in some
patients.53
Direct cardiotoxicity, along with a contribution from neurohor-
monal activation, altered calcium homeostasis, and oxidative stress
have been associated with the development of HF in the setting
of chemotherapy (e.g. anthracyclines, trastuzumab, etc.), chronic
alcohol abuse (alcoholic cardiomyopathy), and exposure to cer-
tain drugs and toxins54–59 (Figure 2). Cardiotoxicity is a relatively
common complication of cancer therapy manifesting as LV dys-
function and HF (usually HFrEF).58 Risk factors for cardiotoxicity
include a history of HF or LV dysfunction (including pre-existing
DCM/HCM), coronary artery disease, hypertensive or valvular
heart disease, as well previous exposure to cardiotoxic drugs
(e.g. anthracyclines) or radiotherapy. Depending on the cardiotoxic
agent and patients’ susceptibility, cardiotoxicity may present soon
after exposure, or it may become clinically evident years after
treatment (late DCM), as a result of progressive myocardial injury
(e.g. 23% of anthracycline-treated patients demonstrated late car-
diotoxicity after a median of 7-year follow-up).60 The prediction
of long-term outcomes in cancer patients is hampered by the fact
that many patients receive multiple drugs and radiotherapy, which
may have a potentiating cardiotoxic effect. Importantly, substantial
© 2019 The Authors
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reversal of LV dysfunction and recovery from HF may occur with
a timely withdrawal of the offending agent(s) and appropriate HF
treatment.
The natural history and outcome of
heart failure in dilated cardiomyopathy
The natural history of HF in DCM can be characterized by
three distinct pathways including: (i) a structural and functional
recovery following incident HF; (ii) a remission of HF symptoms
and improvement/stabilization of LV systolic function; and (iii)
progression to advanced HF and heart transplantation/death.61
Complete functional and structural recovery is infrequent and can
occur if an acute insult did not cause significant myocardial loss,
which allows normalization of LV function once the insult has
resolved. The clinical course of HF in DCM may be variable, but a
substantial functional recovery and reverse LV remodelling can on
occasion be achieved, especially with the use of guideline-directed
medical therapy (GDMT).62,63
Observational data prior to GDMT for the management of HF
indicate that significant clinical improvement occurred in less than
20% of HF patients with DCM, while 77% died within 2 years
of diagnosis, mostly due to progressive pump failure.64 SCD and
systemic embolism, largely attributable to atrial fibrillation (AF),
accounted for the remainder of the cardiovascular mortality.64
Over the last three decades, outcomes have improved with
advances in HF treatment. In a cohort of Japanese DCM patients
enrolled between 1982 and 1989, the 5- and 10-year survival
rates were 61% and 35%, respectively.65 In patients assessed
between 1990 and 2002, the 5- and 10-year survival rates had
increased to 81% and 65%, respectively.65 A favourable prognosis
has been reported with GDMT, demonstrating transplant-free
survival at 1, 2, and 4 years of follow-up in 94%, 92%, and 88%
of patients, respectively.10 Over the same period, survival free
of HF hospitalization was 88%, 82%, and 78%, respectively.10
ICD, cardiac resynchronization therapy (CRT), as well as MCS
and heart transplantation in advanced HF have all provided
further improvements in outcomes, and CRT and MCS in
particular have been associated with reverse remodelling and
recovery.
However, a recent randomized trial (TRED-HF) of 51 patients
with DCM and recovered LV function indicated that withdrawal of
GDMT for HF is associated with a 40% relapse of LV dysfunction
within 6 months.66 This strongly supports continuation of HF
treatment even in patients with recovered DCM.
Besides GDMT, several additional predictors of reverse LV
remodelling have been identified in DCM, which are related
to a more favourable long-term prognosis. In the IMPROVE-HF
study of 3994 HF patients (32% with a non-ischaemic aetiol-
ogy), almost 30% experienced a >10% increase in LVEF over
the 2-year follow-up period. Female sex, a non-ischaemic HF
aetiology and the absence of digoxin use have been identified
as multivariable predictors of LV functional recovery.67 Several
cohort studies have specifically addressed LV functional recovery
in recent-onset DCM and observed a > 10% increase in LVEF



















































































.. end-diastolic diameter have been recognized as independent pre-
dictors of reverse LV remodelling.10 In addition, a lower extent
of late gadolinium enhancement (LGE) on cardiac magnetic reso-
nance (CMR), indicative of lower interstitial replacement fibrosis,
has been shown to provide incremental predictive value for reverse
LV remodelling in recent-onset DCM.8 Importantly, independent of
other factors, LV reverse remodelling was associated with ∼50%
lower mortality rates at 10-year follow-up in DCM patients.68
On the other hand, male sex and advanced age (> 60 years) have
been associated with a poorer prognosis in patients with DCM and
HF.9,10,69 Self-declared black race has also been related to more
severe HF at presentation, a lesser degree of LV reverse remod-
elling and approximately two-fold higher mortality at follow-up.10
Other predictors of adverse outcomes include: lower baseline
LVEF, higher NYHA class (III–IV), significant mitral regurgitation,68
the presence of LBBB and higher natriuretic peptide levels.8,70
Severe functional mitral regurgitation (FMR) has been associated
with approximately two-fold increased risk of mortality or wors-
ening HF in DCM.71 Persistence of severe FMR or worsening
of non-severe FMR despite optimal GDMT has been shown to
predict adverse prognosis in patients with HFrEF, irrespective of
HF aetiology.72 In addition, a more pronounced mid-wall myocar-
dial LGE on CMR has been associated with higher all-cause and HF
mortality and more frequent HF hospitalizations in DCM.70
Heart failure in DCM still carries a considerable mortality risk
that is similar to, or higher than mortality attributed to other
non-ischaemic HF aetiologies (e.g. valvular or hypertensive).11
Advanced HF remains the most frequent cause of death in DCM,
while SCD accounts for < 30% of mortality.9,70 Importantly, DCM
also confers a high risk of non-cardiovascular mortality, as approx-
imately one third of patients die of cancer, infections, pulmonary
disease, or haemorrhage.9,73 The risk of non-cardiovascular death
increases with older age and more severe HF.9,73
Treatment of heart failure in dilated
cardiomyopathy
Both HF-specific and aetiology-related therapies should be consid-
ered for the treatment of HF in DCM.
Heart failure-related therapy
Guideline-directed medical therapy and implantable devices pro-
vide proven outcome benefit for patients with chronic HF in DCM
(Table 1)12,73–85. In acute/advanced HF, in-hospital treatment with
intravenous diuretics, vasodilators, or inotropes may be required,
although there is no evidence that these interventions improve
outcomes.74
Concerns have been raised about the efficacy of certain ther-
apies in patients with DCM, compared with other aetiologies of
HF. Suggestions from observational studies of an increased mor-
tality risk with digoxin and amiodarone in DCM patients with
HF65,67 have not been confirmed in clinical trials.75,86 Prophylac-
tic ICD implantation for primary prevention of SCD is currently
recommended in DCM patients with HF (NYHA class II–III) and
© 2019 The Authors
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Table 1 Outcomes in selected heart failure with reduced ejection fraction clinical trials in patients with idiopathic












. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Medical therapy
SOLVD,12 1991 Enalapril vs.
placebo




Death or hospitalization: RR ↓29%;
Interaction P = NS according to HF
aetiology (ischaemic vs.
non-ischaemic)
DIG,75 1997 Digoxin vs.
placebo
6800; NYHA class I–IV;
LVEF ≤45%
14.1–15.5% Death or HF hospitalization:
RR 0.67 (95% CI 0.58–0.77);
Interaction P = 0.06 according to HF
aetiology (ischaemic vs.
non-ischaemic)
MDC,76 1993 Metoprolol vs.
placebo
383; 94% NYHA class II–III,
LVEF <40%
100% All-cause death:





CIBIS,77 1994 Bisoprolol vs.
placebo
641; NYHA class III (95%) or IV
(5%); LVEF <40%
36% All-cause death:
Placebo vs. bisoprolol: 23/115 vs.
11/117; P = 0.01
RALES,78 1999 Spironolactone vs.
placebo
1663; NYHA class III–IV (NYHA
class IV within 6 months
before enrolment);
LVEF ≤35%
45–46%a All-cause death (overall study
population):
HR 0.70 (95% CI 0.60–0.82);










2028; NYHA class II–IV;
LVEF ≤40%
18.8–20.3% CV death or HF hospitalization
(overall study population):
HR 0.70 (95% CI 0.60–0.81)
No reported interaction according
to HF aetiology
SHIFT,80 2010 Ivabradine vs.
placebo
6558; LVEF ≤35%; sinus rhythm
>70 b.p.m.; NYHA class II–IV;
HF hospitalization within the
previous 12 months
32–33%a CV death or HF hospitalization:
HR 0.72 (95% CI 0.60–0.85);
Interaction P =0.059 according to HF
aetiology (ischaemic. vs.
non-ischaemic)
EMPHASIS-HF,81 2011 Eplerenone vs.
placebo
2737; NYHA class II; LVEF <30%
(or LVEF 30–35% and QRS
>130 ms)
30.1–31.8%a CV death or HF hospitalization
(overall study population):
HR 0.63 (95% CI 0.54–0.74);





10 521; NYHA class II–IV;
LVEF ≤35–40%, BNP ≥150
pg/mL or NT-proBNP ≥600
pg/mL, or HF hospitalization
within the previous 12 months+
BNP ≥100 pg/mL or
NT-proBNP ≥400 pg/mL
39.9–40.1%a CV death or HF hospitalization
(overall study population):
HR 0.80 (95% CI 0.73–0.87)
No reported interaction reported
according to HF aetiology
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Devices
DEFINITE,83 2004 ICD vs. medical
therapy





HR 0.65 (95% CI 0.40–1.06)
Sudden cardiac death:











HR 0.73 (95% CI 0.50–1.07)
Amiodarone vs. placebo,
HR 1.07 (95% CI 0.76–1.51)
Interaction P = NS according to HF











HR 0.91 (95% CI 0.55–1.49)
CRT-D vs. placebo,
HR 0.50 (95% CI 0.29–0.88)
Interaction P = NS according to HF
aetiology (ischaemic vs. non-ischaemic)











HR 0.87 (95% CI 0.68–1.12)
Sudden cardiac death:
HR 0.50 (95% CI 0.31–0.82)
Interaction P = 0.80 according to HF
aetiology (idiopathic vs. valvular vs.
hypertension vs. other)
ACE, angiotensin-converting enzyme; BNP, B-type natriuretic peptide; CI, confidence interval; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization
therapy with defibrillator; CRT-P, cardiac resynchronization therapy with pacemaker; CV, cardiovascular; DCM, dilated cardiomyopathy; GDMT, guideline-directed medical
therapy; HF, heart failure; HR, hazard ratio; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic
peptide; NYHA, New York Heart Association; RR, relative risk; VPC, ventricular premature complexes; VT, ventricular tachycardia.
aProportion of patients with non-ischaemic HF aetiology.
LVEF ≤ 35% on GDMT.74 This was based on earlier clinical tri-
als that have demonstrated a decrease in both arrhythmic and
all-cause mortality in HF of both ischaemic and non-ischaemic
aetiology83,84 (Table 1). The results of the DANISH trial, in which
> 50% of patients received a CRT on top of GDMT, have shown
that ICD implantation reduced the risk of SCD by 50% with no
significant effect on all-cause mortality.73 However, a recent sub-
analysis of the DANISH trial suggested that in patients ≤ 70 years
old, ICD implantation reduced all-cause mortality.87 Also, in the
COMPANION trial, the addition of a defibrillator function to CRT
(i.e. CRT-D) provided a greater reduction in all-cause mortality
in patients with DCM on GDMT compared with patients with an
ischaemic HF aetiology.88 This underscores the need for improve-
ment in risk stratification for CRT eligible patients with DCM who
might derive most benefit from CRT-D for primary prevention.
In addition, approximately one third of patients with DCM may
experience reverse LV remodelling and recovery from HF with



























.. Substantial reverse remodelling is mostly observed with poten-
tially reversible causes of DCM, including alcohol-related, PPCM or
tachycardia-induced cardiomyopathy, underlying the importance of
aetiological assessment of HF in DCM. Those patients possibly may
be protected against SCD during the recovery phase with wearable
defibrillators, thus avoiding the requirement for permanent ICD
implantation.
Correction of LV mechanical dyssynchrony (15–30% of DCM
patients with HF) has a significant positive impact on morbid-
ity and mortality.85,89,90 Hence, CRT is currently recommend for
symptomatic HF patients with LVEF < 35% and QRS ≥130 ms, par-
ticularly of LBBB morphology (a surrogate for LV dyssynchrony),
treated for ≥ 3 months with GDMT, irrespective of HF aetiology.74
Based on the experience from surgical mitral valve repair (MVR)
of moderate-to-severe FMR, suggesting reverse LV remodelling
and functional improvement,91 a percutaneous interventional tech-
nique has been developed for the correction of FMR. Percuta-
neous transcatheter MVR with the MitraClip device demonstrated
similar efficacy but an improved safety compared with surgery.92
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Recently, two randomized clinical trials comparing the effectiveness
of percutaneous MVR with GDMT have demonstrated diverging
results. In the MITRA-FR trial the 1-year risk of death or HF hos-
pitalization did not differ significantly between patients who under-
went percutaneous MVR and those who received GDMT alone.93
Conversely, in the COAPT trial, patients treated with percuta-
neous edge-to-edge repair experienced markedly lower rates of
all-cause mortality and HF hospitalization within 2 years compared
with GDMT alone.94
Aetiology-related therapy
Aetiology-related treatment of HF in DCM is an evolving field,
which needs further evidence from clinical trials. In the case
of inflammatory DCM of autoimmune aetiology without
viral persistence, this treatment includes immunosuppression
and immunoadsorption, whereas, anti-viral agents may be con-
sidered in the setting of biopsy-confirmed acute viral myocarditis
or viral persistence. Several observational and randomized tri-
als have suggested that in virus-negative post-myocarditis DCM
with progressive HF, immunosuppression could be effective
in achieving LV reverse remodelling and improvement in HF
symptoms.95–97 Accordingly, expert consensus documents
have recommended immunosuppression with azathioprine and
prednisone for 6–12 months in patients with biopsy-proven,
virus-negative DCM,35 but the exact role of immunosuppression
is still unresolved. Immunosuppression is also recommended
in acute giant-cell and eosinophilic myocarditis and cardiac
sarcoidosis.7,35,98 In biopsy-proven chronic enteroviral or adenovi-
ral and/or Parvovirus B19 positive DCM, an immunomodulatory
treatment with interferon beta has been recently shown to reduce
viral load and improve functional capacity.99 Small open-label
controlled, or observational studies suggested that removal of
circulating antibodies in DCM by immunoadsorption, followed
by IgG substitution, resulted in improvement in cardiac func-
tion, symptom relief and increased exercise tolerance.100–102
At present, immunoadsorption is considered as an experimental
treatment option that requires further evaluation in outcome tri-
als. In anthracycline-induced cardiomyopathy, timely therapy with
angiotensin-converting enzyme (ACE) inhibitors and beta-blockers
confers a substantial improvement of LVEF.103 Treatment with
the prolactin inhibitor bromocriptine (accompanied by prophy-
lactic anticoagulation) may provide a disease-specific therapy
in patients with acute HF in PPCM.47,104,105 Further aetiologic
therapies include cessation of the offending agent(s) (e.g. alco-
hol) and management of the underlying endocrine or metabolic
disorders.106
In light of the various monogenetic causes of DCM, gene
repair may be a promising target for the causative treatment
of HF. Following improvement in skeletal muscle function with
CRISPR/Cas9 technology for gene repair in Duchenne mus-
cular dystrophy,107 this technology is currently under assess-
ment for genome modification in cardiomyopathies.108 Thus,
the emerging CRISPR/Cas9 technology may become an over-




















































































.. Heart failure in hypertrophic
cardiomyopathy
Incidence and prevalence of heart failure
in hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is defined by an increase in myocar-
dial wall thickness (≥15 mm in adults, or ≥ 13 mm in adults
with first degree relatives with HCM) in one or more of the
LV wall segments, that cannot be explained by abnormal load-
ing conditions.109,110 Most patients have an asymmetric septal
hypertrophy and approximately 40–70% have an obstructive
HCM, diagnosed by a LV intracavitary gradient ≥ 30 mmHg at rest
(∼25% of patients) or during exercise.109,111,112 Non-obstructive
HCM, demonstrating gradients < 30 mmHg at rest and/or with
exercise, is present in 30–60% patients.109,111,112 In several
reports from Europe, Asia and North America, the prevalence
of HCM is 2–5 per 1000 of the general population.113–116 In
60% of patients, HCM results from autosomal dominant sar-
comere gene mutations, whereas other aetiologies including
hereditary syndromes, neuromuscular disorders and storage
diseases characterized by intracellular accumulation of abnormal
substrates (e.g. Anderson–Fabry, Pompe, or Danon disease,
etc.) account for 5–10% of patients110,117 (Figure 4). In about
30% of patients, the cause of HCM remains unknown.109 A
suggested aetiological assessment of HF in HCM is presented in
Figure 1.
Heart failure has two distinct clinical features in HCM; in the
majority of patients, HF is manifested as a HFpEF phenotype, with
specific characteristics in patients with LV obstruction, while only
a minority of patients develop HFrEF at a later stage. Due to a
substantial aetiological and clinical heterogeneity, ascertaining the
incidence of HF in HCM is challenging. Data from a cohort of 1000
patients diagnosed with HCM at mid-adulthood (i.e. 30–59 years
of age) reveal HF incidence of ∼50%, with symptoms varying from
mild to severe (NYHA class II–IV).118 In a contemporary registry of
3208 individuals with cardiomyopathies in Europe, the prevalence
of symptomatic HF in patients with HCM was 67% (NYHA class II
and III–IV symptoms, 49.9% and 17.4%, respectively).119 However,
the mentioned prevalence of HF in HCM might be overestimated
due to possible under-representation of subjects with mild symp-
toms or asymptomatic HCM in registries. HF is prevalent in the
majority of patients with obstructive HCM and in 10% of patients
with non-obstructive HCM.120 Acute HF is infrequent, however
it could be precipitated by conditions such as tachyarrhythmia
(e.g. AF), ischaemia, acute or worsening mitral regurgitation (e.g.
chordal rupture), or co-morbidity (e.g. thyrotoxicosis).109,121,122
Progression to advanced HF (e.g. NYHA class III–IV symptoms)
occurs in 3.5–17% of individuals, usually as a consequence of severe
LV obstruction and hypertrophy, or adverse LV remodelling lead-
ing to systolic dysfunction.123–126 There are no gender or race
distinctions in the prevalence of HF in HCM, but patients with
sarcomere protein disease tend to develop HF at a younger age
and have a higher propensity for progressive HF compared to
patients without mutations.127 Patients with rare inherited dis-
orders (e.g. Anderson–Fabry, Danon, or mitochondrial disease)
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Figure 4 Aetiologies of hypertrophic cardiomyopathy.
Figure 5 Characteristic alterations in cardiac morphology underlying heart failure in hypertrophic cardiomyopathy.
demonstrate multi-system disease, but their clinical presentation is
often (∼60%) dominated by symptoms of HF as well as conduction
abnormalities.128
Amongst HF patients, those with HCM account for 2–3%.16
Accordingly, the proportion of patients with HCM among all heart
transplant recipients for advanced HF is smaller relative to other
aetiologies, because HCM is a rare disease.22 However, compared
with other recipients, patients with HCM tend to be younger and
with fewer co-morbidities at the time of transplantation. This also
accounts for similar or more favourable short-term and long-term
















.. Pathophysiology of heart failure
in hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy due to sarcomere gene
mutations
In genetic HCM, myocyte hypertrophy and disarray occur
in response to impaired energy balance due to the excessive
energy utilization required to generate a hyperdynamic isokinetic
tension within the sarcomere.129,130 Compromised energy bal-
ance, coupled with higher oxygen demand of the hypertrophied
myocardium result in recurrent episodes of demand ischaemia
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(e.g. during exercise or tachycardia) that can explain symptoms
of chest pain, exercise intolerance and exertional dyspnoea.131
In some patients, the underlying pathophysiology may be further
aggravated by haemodynamic overload imposed by a dynamic LV
outflow tract, mid-cavity or multi-level obstruction.132 Coronary
microvascular dysfunction, characterized by structural abnormal-
ities and decreased blood flow in intramural coronary arterioles,
also plays a role in recurrent episodes of myocardial ischaemia and
the development of HF.133 In addition, impaired termination of
contraction at low intracellular Ca2+ levels produces incomplete
myocyte relaxation and diastolic dysfunction, which may both
precede and follow the development of overt hypertrophy.134
In some patients, a cumulative effect of these factors produces
myocyte energy depletion followed by progressive myocyte loss
and replacement fibrosis that eventually lead to adverse LV remod-
elling and progression to systolic dysfunction and HFrEF. Indeed, a
meta-analysis of 1063 HCM patients, followed for an average of
3.1 years, demonstrated that replacement fibrosis on LGE-CMR
predicted a significantly increased risk of mortality due to HF.135 In
a histologic study of 30 explanted hearts with end-stage evolution
of HCM, more than one third of the LV myocardium was replaced
by fibrosis, particularly involving the LV apex and the mid-wall.136
Patients with multiple genetic mutations in sarcomere proteins
(up to 5% of the HCM population) are particularly susceptible to
accelerated progression to end-stage disease.137,138 Also, familial
clustering of advanced HF has been recognized as a marker of risk
for unfavourable outcomes in other family members.126 In addition,
co-morbidities (e.g. myocarditis or epicardial coronary artery dis-
ease) may be rarely associated with adverse LV remodelling and
development of overt HF.111
In patients with obstructive HCM, the severity of HF is prin-
cipally determined by pressure overload imposed by a dynamic
obstruction to LV outflow during systole.120 The characteristic
morphological changes responsible for HF development in HCM
are summarized in Figure 5. The intracavitary obstruction most
commonly involves the outflow tract and is produced by a com-
bination of physical obstruction by the septal hypertrophic tissue,
by an abnormal systolic anterior motion (SAM) of the mitral valve,
and by diastolic and contractile deficits. In 5–10% of patients,
the gradient is exclusively produced by mid-cavity obstruction
due to an abnormal apposition of the hypertrophied septum and
anterolateral papillary muscle.120 Dynamic changes in gradients in
response to changes in myocardial contractility and loading condi-
tions (e.g. exercise, hydration) explain temporal variability and low
reproducibility of HF symptoms in HCM.120 In patients without
a significant gradient at rest, cardiopulmonary exercise testing is
the preferred method for provoking obstruction.109 LV diastolic
dysfunction represents another important mechanism underlying
the development of HF (i.e. HFpEF) in HCM. It is present in the
majority of patients, irrespective of intracavitary obstruction and
is characterized by prolonged isometric relaxation and impaired
filling patterns.111 In addition, mitral valve abnormalities, coronary
myocardial bridging, apical aneurysms, atrial remodelling and
autonomic dysfunction may contribute to the development and
severity of HF.124,139–144 In patients with non-obstructive HCM,



















































































.. HF may have a progressive course culminating in end-stage disease
and severe HFrEF.
Hypertrophic cardiomyopathy due to storage disorders
In patients with HCM caused by rare storage disorders (e.g.
Anderson–Fabry, Danon and Pompe diseases), HF most commonly
takes the HFpEF phenotype due to an extensive, concentric
increase in LV wall thickness.145,146 The increased wall thickness
is caused partly by myocyte hypertrophy (due to lysosomal accu-
mulation of glycosphingolipids), and partly by interstitial fibrosis
stimulated by overproduction of profibrotic cytokines.146 Asym-
metric LV hypertrophy in storage disorders is rare (< 2.5%), while
biventricular hypertrophy may occur in up to 25% of patients.145
In Anderson–Fabry disease, replacement fibrosis (detectable by
LGE-CMR or by strain imaging) within the posterolateral wall
may contribute to LV dysfunction and FMR.147 Most patients
have preserved LVEF with occasional evidence of subaortic LV
obstruction.148 Overt HF is determined by the degree of LV dias-
tolic dysfunction, which correlates with the extent LV hypertrophy
and N-terminal pro B-type natriuretic peptide (NT-proBNP)
levels.149 Rarely, diastolic dysfunction in storage disorders may
progress to a restrictive filling pattern, accompanied by a signifi-
cant biatrial enlargement.145 In those patients, cardiac involvement
may take the characteristics of an RCM; thus, storage disorders
need to be considered as underlying aetiology of both HCM and
RCM. Development of LV systolic dysfunction and HFrEF invariably
occurs in Danon disease and occasionally in patients with other
metabolic cardiomyopathies.150
The natural course and outcome of heart
failure in hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy due to sarcomere gene
mutations
Typically, LV hypertrophy in HCM caused by sarcomere disorders
develops in adolescence or early adulthood (although it may
present from early childhood to the seventh decade), and remains
stable with preserved LV systolic function and variable degrees
of LV diastolic dysfunction.151 In patients with obstructive HCM,
the severity and prognosis of HF are principally influenced by LV
outflow obstruction. This is highlighted by data demonstrating
that a gradient ≥ 30 mmHg at rest independently predicted HF
progression and increased mortality.152 Recent findings from a
cohort of 324 patients with obstructive HCM and mild HF at
baseline, demonstrated progression to NYHA functional class
III–IV, at an annual rate of 3.2–7.4% depending on the degree of
outflow tract obstruction.153 As a result, severe HF was prevalent
in 20–38% of those patients following a period of 6.5 years.153
Similarly, in a cohort of 293 HCM patients followed up for a median
of 6 years, advanced HF developed in 20% of those with severe
obstruction to LV outflow.123 The distinguishing features of these
patients were older age (50± 14 years) and a significantly increased
LV wall thickness at baseline.123
Mid-cavity obstruction is often accompanied by severe HF symp-
toms and impaired survival. In a cohort of 423 patients, a mid-cavity
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obstruction was identified in 8% of patients that were more symp-
tomatic (> 90% with NYHA class ≥ II) and had higher mortality
compared with the rest of the cohort.154
Severe diastolic dysfunction (i.e. restrictive filling pattern) can
be demonstrated in up to 9.2% of patients with HCM, usually
in the setting of severe myocardial hypertrophy, with or without
LV outflow tract obstruction. These patients generally present
with symptoms of low cardiac output (rather than with overt
congestion), and they have an independently increased risk of
progression to advanced HF and end-stage disease.123,155 In one
study, those patients accounted for 48% of advanced HF cases, and
as a result of restrictive filling pattern they had significant left atrial
enlargement et entry or during follow-up.
In patients with non-obstructive HCM, the disease usually has
a benign and stable course and the majority remains free of HF
or has mild symptoms due to diastolic dysfunction. However, in
7–10% of patients with non-obstructive HCM (incidence, 1.6% per
year),120,156 the disease can have a progressive course character-
ized by LV dilatation, wall thinning, and development of LV systolic
dysfunction, including an LVEF in the low-normal range.151,157
Adverse LV remodelling is subtended by extensive myocardial
replacement fibrosis.151,158 The most advanced, ‘burned-out’,
phase occurs in 3% of patients and carries a considerable risk of
mortality (11% per year).126
In addition, left and right atrial enlargement have been rec-
ognized as independent predictors of adverse outcomes in
HCM.123,153,159 Likewise, the occurrence of AF, usually at a
younger age than in the general population, significantly increases
the risk of a detrimental clinical course.121,123
Hypertrophic cardiomyopathy due to storage disorders
In patients with HCM due to hereditary storage disorders, HF
may become apparent at any time from childhood to the mature
age depending on the extent of cardiac involvement, in rela-
tion to the severity of enzyme deficit.160 In Anderson–Fabry dis-
ease, the development of overt HF has been reported in 23% of
patients usually between the third and the fifth decade of life.161
The progression to advanced HF has been observed in 10% of
patients over a median period of 7.1 years.162 Increased levels of
cardiac biomarkers (troponin T, NT-proBNP) and higher extent
of fibrosis have been associated with a reduction in LVEF dur-
ing the follow-up.163 Cardiac disease may progress to LV systolic
dysfunction and HFrEF in 6–8% (in particular in the absence of
enzyme replacement therapy) and confers a great risk of HF-related
mortality.164,165
Treatment of heart failure
in hypertrophic cardiomyopathy
Treatment of HF in patients with HCM encompasses general HF
and aetiology-related treatment.
The first-line therapy of patients with HCM should include
non-vasodilating beta-blockers to reduce contractility and alleviate
the consequences of LV diastolic dysfunction by lowering heart



















































































.. symptoms of HF, while avoiding hypovolaemia. In patients with an
intolerance or a contraindication to beta-blockers, verapamil or
diltiazem could be an alternative. However, there is a paucity of
evidence on how these medications influence the natural course
and outcomes in HCM.109
In patients with obstructive HCM and preserved LVEF,
who remain symptomatic despite maximal tolerated doses of
beta-blockers, disopyramide could be considered as a second-line,
add-on therapy.109 Disopyramide exerts a negative inotropic effect
that can reduce LV outflow tract gradient in the majority of
patients and improve HF symptoms, without affecting mortality,
or causing proarrhythmia.166 In patients with obstructive HCM,
who have a gradient ≥ 50 mmHg at rest, or during exercise,
and remain symptomatic (NYHA class III–IV) despite GDMT,
invasive gradient reduction with surgical septal myectomy or
septal alcohol ablation should be considered.109 Surgical septal
myectomy has been shown to abolish or significantly reduce
obstruction in > 90% of patients treated in experienced cen-
tres, followed by a long-term improvement in HF symptoms
and extended survival.167,168 Alternatively, alcohol septal ablation
has been shown to convey an improvement in outcomes com-
parable with surgery.169 Surgery seems less beneficial for older
patients and for those with residual AF.170 Alcohol septal ablation
may be less effective in younger patients with higher baseline
gradients.171 The periprocedural complications of both proce-
dures include atrioventricular block (7–20% of patients), bundle
branch block, or ventricular septal defect.109 These treatment
modalities are currently available in a small number of experienced
centres.
Dual-chamber pacing has failed to demonstrate convincing treat-
ment benefits.172 It is currently recommended in patients with
obstructive HCM (and an indication for antibradycardia pacing),
deemed unsuitable for, or unwilling to undergo surgery/alcohol
septal reduction.109
Patients with HCM are at an increased risk of SCD. For primary
prevention, European Society of Cardiology guidelines recommend
the use of a validated prediction model (i.e. HCM Risk-SCD) to
estimate an individual 5-year risk of SCD109 (Figure 6). Specifically,
in patients with HF due to HCM, additional features may be used
to refine risk assessment for SCD,126,140,173 but their incremental
prognostic value compared with HCM Risk-SCD remains unknown
(Figure 6). Of note, HCM Risk-SCD has not been validated in
patients with storage/metabolic causes of HCM, or following myec-
tomy/septal ablation.
Patients with non-obstructive HCM and reduced LVEF (< 50%)
should be treated with GDMT for HFrEF.109 In a setting of progres-
sive LV dysfunction, refractory HF symptoms and LBBB, limited
data supports CRT implantation in patients with LVEF < 50%,174
whereas patients with LVEF ≤ 35% and LBBB should be considered
for CRT implantation as per current guidelines for the management
of HF.74
In patients with HCM and advanced HF, long-term MCS is
rarely considered suitable as a bridge to transplantation due to
small LV cavity dimensions and severely impaired filling. How-
ever, a small study suggested an improvement in outcomes in
HCM patients with an LV assist device comparable to patients
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Figure 6 Sudden cardiac death (SCD) risk assessment in patients with heart failure (HF) and hypertrophic cardiomyopathy (HCM). ICD,
implantable cardioverter-defibrillator; LA, left atrial; LGE, late gadolinium enhancement; LV, left ventricular; NSVT, non-sustained ventricular
tachycardia. *In selected low-to-moderate risk patients based on HCM Risk SCD assessment, an ICD may be recommended in the presence
of additional markers of increased SCD risk, following careful consideration of potential complications.
Table 2 Therapies of lysosomal storage disorders: relevance for the management of heart failure
Anderson–Fabry disease
Enzyme replacement therapy: agalsidase-𝛼
or agalsidase-𝛽
• Reduction in left ventricular mass index and a significant increase in mid-wall fractional shortening
• Improvement in a composite cardiac, renal and cerebrovascular outcome or mortality
• Partial loss of therapeutic effectiveness due to antibody formation may be alleviated by
immunomodulators or a combination with an oral chaperone
Oral chaperon: migalastat • Similar effect on a composite renal, cardiovascular and cerebrovascular outcome compared with
enzyme replacement therapy
• Possible positive impact on left ventricular fibrosis and hypertrophy
Pompe disease
Enzyme replacement therapy: 𝛼-glucosidase • Regression of left ventricular hypertrophy (if administered early in the course of the disease)
According to ref. 176, 177, 179–182
with DCM, but with a higher risk of complications.175 Heart
transplantation should be considered in patients who progress
to advanced HF despite GDMT. At the time of transplantation
most patients demonstrate significant LV systolic dysfunction
(i.e. ‘burned-out’ phase). A small proportion of HCM patients
may require heart transplantation for advanced HF despite
preserved LVEF.157
Treatment of patients with storage disorders
For patients with HCM occurring in Anderson–Fabry dis-
















.. with agalsidase-𝛼 and agalsidase-𝛽,176–178 or with an oral chap-
erone, migalastat,179,180 that should be instituted as early as
possible (Table 2). For patients with Pompe disease (glycogen
storage disease type II), enzyme replacement therapy with recom-
binant human 𝛼-glucosidase is available (Table 2).181,182 Since no
specific therapy is available for patients with Danon disease, a
close follow-up is recommended due to the malignant nature
of the disease, including low threshold for ICD implantation
and early listing for heart transplantation in appropriate
candidates.183
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Heart failure in restrictive
cardiomyopathy
Incidence and prevalence of heart failure
in restrictive cardiomyopathy
Restrictive cardiomyopathy is defined by the presence of restrictive
physiology in patients with normal or reduced diastolic volumes
of one or both ventricles, and normal or reduced systolic
volumes.110 Ventricular wall thickness is usually normal; however, in
infiltrative or storage disease aetiologies of RCM, there is a variable
degree of ventricular wall thickening.184 The aetiology of RCM is
heterogeneous, including idiopathic, hereditary and acquired cases
of non-infiltrative and infiltrative myocardial disorders, storage dis-
eases and endomyocardial disorders (Figure 7). Importantly, the
clinical phenotype of cardiomyopathy due to specific aetiologies
may demonstrate and overlap between HCM and RCM (e.g. in
Anderson–Fabry, Pompe and Danon diseases), or a transformation
from an RCM to DCM due to progressive nature of the underly-
ing disorder (e.g. haemochromatosis/iron overload, amyloidosis).
The prevalence of RCM is currently unknown, but it is the least
frequent amongst the cardiomyopathies.110,185
The principal clinical manifestation of RCM is HFpEF, with
signs and symptoms of right, left or biventricular HF. HFrEF may
present at the late stage of the disease, and is more prevalent
in cardiac amyloidosis and iron overload/haemochromatosis.186,187
These aetiologies need to be considered in differential diagnosis
between RCM and DCM (Figure 1). In addition, RCM is character-
ized by a greater risk of thromboembolism, conduction abnormal-
ities, arrhythmias and SCD.188
The prevalence of HF in patients with RCM is high, as evidenced
by a large European registry of cardiomyopathies, in which HF
was prevalent in 83% of patients with RCM (NYHA class II, III,
and IV present in 41%, 40% and 1.6%, respectively).119 Similarly,
in a cohort of 97 patients with primary RCM, 81% had overt HF,
with 53% of patients demonstrating symptoms in NYHA class
II, and 28% in NYHA class III–IV.189 In adults with echocardio-
graphically confirmed RCM (performed for screening because of a
family history of HCM), 63% of patients presented with HF, while
incident HF occurred in 89% of those patients during the 5-year
follow-up.190 Among individuals > 65 years of age, RCM due to
cardiac amyloidosis may be an underrecognized, albeit important
cause of unexplained HF.191 In a series of patients ≥ 90 years of
age who died of HF, autopsy revealed RCM in 10%.192 Studies
using a scintigraphy to diagnose transthyretin amyloidosis (ATTR)
demonstrated a 16% prevalence among patients undergoing percu-
taneous aortic valve replacement for severe low-flow, low-gradient
aortic stenosis193 and a 13% prevalence among patients
with HFpEF.194
Pathophysiology of heart failure
in restrictive cardiomyopathy
The hallmark of RCM is increased ventricular wall stiffness
caused by abnormalities intrinsic to the myocardium, or to the



















































































.. ventricular stiffness has been attributed to increased myofila-
ment sensitivity to calcium, increased deposition of collagen
type III, and intracellular aggregates of the mutant protein such
as desmin or filamin C.186 In infiltrative and storage diseases,
extracellular or intracellular accumulation of the pathological
material in the myocardium accompanied by cardiomyocyte hyper-
trophy and variable interstitial and/or replacement fibrosis are
responsible for increased myocardial stiffness. Endomyocardial
fibrosis (EMF) caused by hypereosinophilic syndrome, carcinoid
and exposure to chemo/radiotherapy may also result in restric-
tive pathophysiology.195 Irrespective of the aetiology, RCM is
characterized by severe diastolic dysfunction, presenting with a
restrictive filling abnormality.110 Markedly elevated filling pressure
leads to prominent biatrial enlargement, and a predisposition
to AF, which further diminishes ventricular filling.184 Although
ventricular systolic function is preserved in RCM, stroke volume
may be decreased because impaired diastolic filling fails to provide
sufficient preload. Consequently, patients with RCM typically have
low-to-normal blood pressure, and may suffer from orthostatic
hypotension and hypoperfusion if volume is depleted (e.g. due to
excessive diuresis).
Although cardiac amyloidosis is often considered as a cause of
HFpEF since LVEF often remains preserved until the late stage of
the disease, in the majority of patients with HF, LV systolic function
is also compromised due to a reduction in LV longitudinal function
and strain.196 Furthermore, myocardial contractility and inotropic
reserve during exercise are also reduced in almost all patients with
HF.197,198
The natural course and outcome of heart
failure in restrictive cardiomyopathy
The prognosis of HF in RCM is poor, regardless of the underlying
cause of RCM.195 In a small cohort of paediatric patients with
primary RCM, an extraordinary 53% experienced SCD shortly
after diagnosis; 75% of the remaining patients had HF, and all had
died or underwent heart transplantation within a few years of
diagnosis.199 In adult patients with RCM and a confirmed genetic
background, the 5-year survival rate was 56%, and the main cause
of death was HF (42%).190 Likewise, in a study of patients with
idiopathic RCM (10–90 years of age), the 5-year mortality rate was
50%, and 68% of patients died of cardiovascular causes, including
HF.189 The risk of death doubled with each increment in NYHA
class, independently of other characteristics.189
Caused by intramyocardial deposition of transthyretin-derived
amyloid fibrils, transthyretin amyloid cardiomyopathy is the most
common cause of the infiltrative form of RCM.200
Although there are > 30 amyloidogenic proteins, the two most
common types of amyloidosis are the immunoglobulin light chain
amyloidosis (AL) and ATTR amyloidosis; the latter comprises a
mutant transthyretin form (ATTR-m) and a ‘wild-type’ transthyretin
form (ATTR-wt). Cardiac involvement is the principal determinant
of mortality in AL amyloidosis due to rapid loss of contractile
function and a transition from HFpEF to HFrEF.201 A direct toxicity
of amyloidogenic light chains by increased oxidative stress has
been implicated in myocardial damage, which is often out of
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Figure 7 Aetiologies of restrictive cardiomyopathy.
Figure 8 Characteristic alterations in cardiac morphology underlying heart failure in restrictive cardiomyopathy.
proportion to amyloid deposition.201 This may explain severe
and progressive HF in patients with seemingly mild-to-moderate
cardiac involvement.202 HF in AL amyloidosis is often manifested as
right HF and frequently unresponsive to conventional treatment; a
median survival of patients is approximately 6 months, whilst the
5-year survival rate is <10%.203,204 In addition to progressive HF,
a significant proportion of patients die suddenly, mostly due to
pulseless electrical activity for which ICD therapy is ineffective.202
Amyloid deposits may also cause conduction system abnor-
malities, ventricular and supraventricular arrhythmia, valvular















.. and pericardial effusion, which all contribute to significant mor-
bidity and mortality.186,188 Increased levels of NT-proBNP and
troponin T, and extracellular volume expansion on CMR T1
mapping have been shown to strongly predict poor survival
in AL amyloidosis.205,206 Patients with ATTR amyloidosis (par-
ticularly those with ATTR-wt or ‘senile amyloidosis’) have a
longer median survival of 24–66 months compared with AL
amyloidosis; nevertheless, the prognosis is poor.207 ATTR-wt
has become increasingly recognized as a cause of unexplained
HFpEF in elderly patients with biatrial enlargement, mild mitral
or tricuspid regurgitation, AF and/or conduction abnormalities.194
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It is frequently accompanied by carpal tunnel syndrome and
autonomic neuropathy.208 A worse survival has been demon-
strated with increasing levels of NT-proBNP and troponin T, and
a risk stratification scheme based on cardiac biomarkers has been
proposed.194
Clinically manifest cardiac involvement occurs in ∼5% of patients
with sarcoidosis, with a male predominance.209 However, autopsy
findings reveal cardiac involvement in at least 25% of patients with
sarcoidosis.210,211 Isolated cardiac sarcoidosis may precede sys-
temic manifestations.212 Clinical presentation depends on the bur-
den and location of granulomatous infiltration, which most com-
monly affects the LV myocardium.209 The resulting cardiomyopa-
thy is either of a DCM type (more common) or an RCM type
(less common) and overt HF is present in 10–40% of patients
with cardiac sarcoidosis.186 Previously undiagnosed sarcoidosis has
been identified as an underlying cause of advanced HF in ∼3%
of patients requiring MCS or heart transplantation.213,214 There is
also a higher risk of high-degree atrioventricular block215,216 and
ventricular tachycardia,217 and there may be an increased risk of
SCD.209,214 The presence and severity of HF have been identified
as important predictors of mortality in patients with sarcoidosis,
with the expected 10-year transplantation-free survival of only 53%
in individuals with overt HF.212,218
Increased gastrointestinal iron absorption in haemochromato-
sis, and chronic blood transfusions in hereditary anaemias (e.g.
thalassaemia, sickle cell anaemia), advanced renal insufficiency, and
several haematological disorders (e.g. myelodysplastic syndrome),
produce an iron overload state characterized by excessive cel-
lular uptake of non-transferrin bound iron.187 Iron excess in the
myocardium produces an impairment in transmembrane Ca2+ flux
and diastolic dysfunction, followed by progressive myocyte loss,
replacement fibrosis, and chamber dilatation due to direct cyto-
toxic effects of accumulated iron.219,220 If left untreated, cardiac
involvement in iron overload/haemochromatosis advances from
an early stage of an RCM with a HFpEF phenotype, to a late
stage of a DCM with a HFrEF phenotype.187 Less frequently, in
elderly patients with severe iron overload, restrictive LV patho-
physiology promotes the development of pulmonary hypertension,
right ventricular remodelling and failure, without LV dilatation.221
The occurrence of HF portends a poor prognosis, and < 50% of
patients with thalassaemia survive up to 5 years following the onset
of HF.222,223 Early identification and follow-up of cardiac involve-
ment with NT-proBNP levels, echocardiography (in particular tis-
sue Doppler and strain rate imaging) and CMR is highly relevant for
the management of patients with iron overload syndromes224–227
(Figure 1).
Endomyocardial fibrosis is the most frequently encountered
endomyocardial disorder and is the leading cause of RCM in trop-
ical regions of Africa, Asia and South America.228 Although the
aetiology of EMF is still elusive, genetic, dietary, and infectious
factors may promote inflammation responsible for endomyocardial
damage and fibrosis.228 The disease affects young and middle-aged
individuals, beginning with an active phase of eosinophilic inflam-
mation, followed by scar formation and a high risk for intracav-



















































































.. a chronic phase, in which RCM prevails, with signs and symp-
toms of biventricular or right-sided HF.229 The clinical presenta-
tion of HF is often dominated by massive ascites, which is out of
proportion to peripheral oedema. As a result of increased filling
pressures, significant mitral and tricuspid regurgitation and AF are
frequently encountered.230 Overt HF carries an ominous progno-
sis with a 75% mortality rate at 2 years.231 EMF accounts for 20%
of HF hospitalizations and 15% of cardiac deaths in the endemic
regions.232,233
In hypereosinophilic syndrome (formerly, Loeffler’s endocardi-
tis), which is characterized by persistently elevated eosinophil
blood count (>1.5 × 109/L), cardiac morbidity is caused by the
release of biologically active substances that damage the endothe-
lium and myocardium.186 Although occurring outside tropical
regions, hypereosinophilic syndrome bears a striking resemblance
to EMF with respect to the pathogenesis and clinical presenta-
tion of RCM.186 In rare cases, carcinoid heart disease and car-
diac fibroelastosis need to be considered as underlying causes
of RCM.
Treatment of heart failure in restrictive
cardiomyopathy
Conventional treatment of HF in RCM includes recommenda-
tions on fluid and sodium restriction (particularly in patients
with hyponatremia) and judicious use of loop diuretics and min-
eralocorticoid receptor antagonists since over-diuresis may lead
to low output hypotension in the presence of restrictive filling
abnormalities. Similarly, ACE inhibitors, or angiotensin receptor
blockers may cause hypotension even at low-to-moderate doses,
whereas beta-blockers may be poorly tolerated due to an increased
risk of worsening HF (because a fixed stroke volume requires
a higher heart rate to maintain cardiac output).188 Therefore,
in patients with RCM, these medications need to be used with
caution. Tachyarrhythmias are often poorly tolerated and require
prompt rate or rhythm control. There is an unresolved issue
of an ICD implantation for primary prevention in patients with
RCM and preserved LVEF. At present, pending clinical trial evi-
dence, expert consensus suggests an individualized assessment of
arrhythmic risk, aetiology, multi-organ involvement and survival
expectancy. There is limited experience with MCS in RCM patients
with advanced HF. However, data from a small cohort of RCM
patients treated with MCS demonstrate improved survival irre-
spective of aetiology (i.e. amyloidosis vs. other aetiologies), espe-
cially among patients with larger LV dimensions.234 Heart trans-
plant or heart/liver transplant (in patients with ATTR-m) can be
considered in patients with advanced HF unresponsive to medical
treatment.235
Specific therapies should be considered after the aetiology of
RCM has been established. The major goal of treatment for cardiac
amyloidosis is to inhibit the production, and to reduce the bur-
den of amyloid protein infiltration. For AL amyloidosis, the estab-
lished treatment strategy is chemotherapy, potentially combined
with autologous stem cell transplantation. A recent retrospective
study has reported that a combination of bortezomib, dexametha-
sone, and an alkylating agent has been associated with improved
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survival in patients with HF due to AL amyloidosis.236 Recently,
a significant breakthrough in the treatment of cardiac amyloidosis
(ATTR-m and ATTR-wt) has been observed with an oral acting
transthyretin stabilizer, tafamidis. In the ATTR-ACT randomized
trial, tafamidis has been associated with 30% reductions in all-cause
mortality and cardiovascular-related hospitalizations and a reduc-
tion in the decline in functional capacity and quality of life compared
with placebo.237 Currently, tafamidis is approved in Europe for the
treatment of ATTR amyloidosis in adult patients with polyneu-
ropathy. Another strategy including pharmacological inhibition of
transthyretin gene expression with patisiran has shown promis-
ing results in decreasing adverse cardiac outcomes compared with
placebo in a subset of patients with cardiac ATTR-m amyloidosis.238
Observational data suggest that ventricular dysfunction and
heart rhythm abnormalities can improve with immunosuppression
in cardiac sarcoidosis.239 In a Finnish registry (96% of patients
on immunosuppression), transplantation-free survival at 1, 5 and
10 years was 97%, 90%, and 83%, respectively.212 The choice of
the most effective immunosuppressive therapy and the duration
of treatment remain yet to be determined. Importantly, a regular
follow-up to detect possible relapses is recommended.
In iron overload/haemochromatosis, improvement in cardiac
function has been noted with timely and sustained iron removal.240
In patients with haemochromatosis, phlebotomy removes 200 to
250 mg of iron at each session, and should be performed once or
twice weekly to reduce serum ferritin to < 1000 ng/mL (or <1000
𝜇g/L).241 Chelation therapy is an effective alternative option when
phlebotomy is not feasible, such as in patients with chronic anaemia
or malignancy. Iron chelation treatment can improve prognosis and
survival in patients with iron overload.242
In hypereosinophilic syndrome affecting the heart, treatment
with corticosteroids alone, or in combination with hydroxyurea
or interferon-𝛼, during the acute stage of the disease can result in
improvement in LVEF and symptoms.243 Imatinib may be also use-
ful for the treatment of hypereosinophilic syndrome.244 By analogy,
corticosteroids and immunosuppressive drugs may be used in the
early stages of EMF, but there are no randomized trials to support
this approach.228 There is also evidence that cardiac surgery (endo-
cardectomy with or without valve repair/replacement) performed
in experienced centres can increase survival compared with medi-
cal treatment in EMF.245
Summary
Comprehensive understanding of the epidemiology, underlying
mechanisms, natural course and recent therapeutic advances can
have a far-reaching impact on the management and prognosis
of patients with HF in cardiomyopathies. Amongst cardiomy-
opathies, DCM is the most prevalent cause of HF. HFrEF is the most
frequent presenting manifestation, as well as the predominant cause
of death in DCM. Also, advanced HF in DCM is one of the
leading indications for heart transplantation. In HCM, HF occurs
less frequently than in DCM and usually takes the phenotype



















































































.. and ∼10% of patients with non-obstructive HCM. A timely recog-
nition and treatment of patients at risk of progressive HF is impor-
tant, since development of advanced HF, although rare in HCM,
confers a poor prognosis. Although RCM is the least common
amongst the cardiomyopathies, the majority of patients present
with HFpEF, while HFrEF usually occurs at a later stage and is
more frequent in amyloidosis or iron overload/haemochromatosis.
Regardless of the underlying aetiology, HF in RCM is a predictor
of a poor outcome.
Recently, new insights have occurred into the initiating causes
and prevailing mechanisms of HF development in several car-
diomyopathies. In addition, novel aetiology-specific therapies,
including transthyretin stabilizers in cardiac amyloidosis, enzyme
replacement therapies in Anderson–Fabry and Pompe diseases,
immunoadsorption, immunotherapy, and selective administration
of antiviral agents in DCM, as well as bromocriptine in PPCM,
have shown a potential to improve outcomes beyond GDMT of
HF. Still, causative therapies of many cardiomyopathies are lacking,
which emphasizes the importance of developing evidence-based
management that would improve outcomes in a majority of
patients with HF in cardiomyopathies.
Conflict of interest: none declared.
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